Concepedia

Ravi Jahagirdar

RJ

Statistics

Publications

10

Citations

866

H-Index

10

Active since

2006

Affiliations

Resverlogix (Canada)(Current)

University of California, Irvine

VA Palo Alto Health Care System

Ravi Jahagirdar is an author at Resverlogix (Canada) specializing in inflammation, molecular biology, and life sciences.

Publications per year

2006–2022

10

Publications

10

RVX-208

Dana Bailey, Ravi Jahagirdar, Allan Gordon et al. · Journal of the American College of Cardiology · 2010 · 229 citations

Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension

Diederik E. van der Feen, Kondababu Kurakula, Ève Tremblay et al. · American Journal of Respiratory and Critical Care Medicine · 2019 · 163 citations · Full text

Medicine, Cardiology, Molecular Biology +15

A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice

Ravi Jahagirdar, Haiyan Zhang, Salman Azhar et al. · Atherosclerosis · 2014 · 131 citations

Life Sciences, Biochemistry, Pharmacotherapy +14

Peroxisome proliferator-activated receptor-α selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice

Rai Ajit K. Srivastava, Ravi Jahagirdar, Salman Azhar et al. · Molecular and Cellular Biochemistry · 2006 · 97 citations

Medicine, Biochemistry, Endocrinology +15

Apabetalone downregulates factors and pathways associated with vascular calcification

Dean Gilham, Laura Tsujikawa, Christopher D. Sarsons et al. · Atherosclerosis · 2018 · 66 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +16

1–5 of 10